Recommended Cash Tender Offer for MedImmune by AstraZeneca

Pursuant to the merger agreement with MedImmune, Inc. announced on 23 April, AstraZeneca PLC announces that its wholly-owned subsidiary, AstraZeneca Biopharmaceuticals Inc., today commenced a cash tender offer to acquire all outstanding shares of MedImmune’s common stock, par value $0.01 per share, at a price of $58.00 per share. The tender offer is scheduled to expire at 12:00 Midnight, New York City time, on Thursday, May 31, 2007, unless extended. Details of the tender offer are contained in the documents that are being sent to MedImmune stockholders and will be posted on astrazeneca.com/astrazeneca.se. -Ends- 3 May 2007 AstraZeneca Media Enquiries Steve Brown / Edel McCaffrey (London): +44 020 7304 5033/5034 Staffan Ternby (Sweden): 08 553 26107 Emily Denney (Wilmington): +1 302 885 3451 Analyst / Investor Enquiries Jonathan Hunt /Mina Blair / Karl Hård (London): +44 020 7304 5087/5084/5322 Staffan Ternby (Sweden): 08 553 26107 Ed Seage / Jorgen Winroth (US): +1 302 886 4065/ (212) 579 0506 Merrill Lynch (Financial Adviser to AstraZeneca) Richard Girling: +44 020 7628 1000 Deutsche Bank (Joint Corporate Broker to AstraZeneca) Charlie Foreman: +44 020 7545 8000 Goldman Sachs (Joint Corporate Broker to AstraZeneca) Phil Raper: +44 020 7774 1000